Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.
| Revenue (Most Recent Fiscal Year) | $10.00M |
| Net Income (Most Recent Fiscal Year) | $-113.62M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.89 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -833.60% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -12.93% |
| Return on Assets (Trailing 12 Months) | -12.23% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $15.91 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.39 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.83 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.84 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 60.98M |
| Free Float | 56.17M |
| Market Capitalization | $840.36M |
| Average Volume (Last 20 Days) | 0.93M |
| Beta (Past 60 Months) | 2.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.39% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |